Nepstar Going Private As Wider China Meltdown Creates Relisting Uncertainties
This article was originally published in PharmAsia News
Executive Summary
Another U.S.-listed Chinese healthcare firm is going private on the heels of Mindray, Wuxi, and China Cord Blood. But the current severe turbulence in China’s stock markets could complicate the prospects of relisting for other companies that have already taken this route and may be looking at re-offering their shares.